Resistance Patterns among Multidrug-Resistant Tuberculosis Patients in Greater Metropolitan Mumbai: Trends over Time

被引:52
|
作者
Dalal, Alpa [1 ]
Pawaskar, Akshay [2 ]
Das, Mrinalini [3 ]
Desai, Ranjan [4 ]
Prabhudesai, Pralhad [5 ]
Chhajed, Prashant [6 ]
Rajan, Sujeet [7 ]
Reddy, Deepesh [8 ]
Babu, Sajit [9 ]
Jayalakshmi, T. K. [10 ]
Saranchuk, Peter [3 ]
Rodrigues, Camilla [11 ]
Isaakidis, Petros [3 ]
机构
[1] Jupiter Hosp, Thana, India
[2] Vasant Vihar, Thana, India
[3] Med Sans Frontieres MSF Doctors Borders, Bombay, Maharashtra, India
[4] GTB Hosp, Bombay, Maharashtra, India
[5] Lilavati Hosp, Bombay, Maharashtra, India
[6] Fortis Hosp, Bombay, Maharashtra, India
[7] Bhatia Hosp, Bombay, Maharashtra, India
[8] Observer Res Fdn, Bombay, Maharashtra, India
[9] LH Hiranandani Hosp, Bombay, Maharashtra, India
[10] Dr DY Patil Hosp, Navi Mumbai, India
[11] PD Hinduja Natl Hosp & Med Res Ctr, Bombay, Maharashtra, India
来源
PLOS ONE | 2015年 / 10卷 / 01期
关键词
DRUG-RESISTANCE; INDIA;
D O I
10.1371/journal.pone.0116798
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background While the high burden of multidrug-resistant tuberculosis (MDR-TB) itself is a matter of great concern, the emergence and rise of advanced forms of drug-resistance such as extensively drug-resistant TB (XDR-TB) and extremely drug-resistant TB (XXDR-TB) is more troubling. The aim of this study was to investigate the trends over time of patterns of drug resistance in a sample of MDR-TB patients in greater metropolitan Mumbai, India. Methods This was a retrospective, observational study of drug susceptibility testing (DST) results among MDR-TB patients from eight health care facilities in greater Mumbai between 2005 and 2013. We classified resistance patterns into four categories: MDR-TB, pre-XDR-TB, XDR-TB and XXDR-TB. Results A total of 340 MDR-TB patients were included in the study. Pre-XDR-TB was the most common form of drug-resistant TB observed overall in this Mumbai population at 56.8% compared to 29.4% for MDR-TB. The proportion of patients with MDR-TB was 39.4% in the period 2005-2007 and 27.8% in 2011-2013, while the proportion of those with XDR-TB and XXDR-TB was changed from 6.1% and 0% respectively to 10.6% and 5.6% during the same time period. During the same periods, the proportions of patients with ofloxacin, moxifloxacin and ethionamide resistance significantly increased from 57.6% to 75.3%, from 60.0% to 69.5% and from 24.2% to 52.5% respectively (p<0.05). Discussion The observed trends in TB drug-resistance patterns in Mumbai highlight the need for individualized drug regimens, designed on the basis of DST results involving first- and second-line anti-TB drugs and treatment history of the patient. A drug-resistant TB case-finding strategy based on molecular techniques that identify only rifampicin resistance will lead to initiation of suboptimal treatment regimens for a significant number of patients, which may in turn contribute to amplification of resistance and transmission of strains with increasingly advanced resistance within the community.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Risk factors for the occurrence of multidrug-resistant tuberculosis among patients undergoing multidrug-resistant tuberculosis treatment in East Shoa, Ethiopia
    Fanta Desissa
    Tilaye Workineh
    Takele Beyene
    BMC Public Health, 18
  • [22] Hypokalemia among patients receiving treatment for multidrug-resistant tuberculosis
    Shin, SY
    Furin, J
    Alcántara, F
    Hyson, A
    Joseph, K
    Sánchez, E
    Rich, M
    CHEST, 2004, 125 (03) : 974 - 980
  • [23] Predictors for Mortality among Multidrug-Resistant Tuberculosis Patients in Tanzania
    Mollel, Edson W.
    Chilongola, Jaffu O.
    JOURNAL OF TROPICAL MEDICINE, 2017, 2017
  • [24] Cavitary Penetration of Levofloxacin among Patients with Multidrug-Resistant Tuberculosis
    Kempker, Russell R.
    Barth, Aline B.
    Vashakidze, Sergo
    Nikolaishvili, Ketino
    Sabulua, Irina
    Tukvadze, Nestani
    Bablishvili, Nino
    Gogishvili, Shota
    Singh, Ravi Shankar P.
    Guarner, Jeannette
    Derendorf, Hartmut
    Peloquin, Charles A.
    Blumberg, Henry M.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (06) : 3149 - 3155
  • [25] Multidrug-resistant tuberculosis among previously treated patients in the Philippines
    Gler, M. T.
    Macalintal, L. E.
    Raymond, L.
    Guilatco, R.
    Quelapio, M. I. D.
    Tupasi, T. E.
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2011, 15 (05) : 652 - 656
  • [26] Molecular Diagnosis of Multidrug-Resistant Mycobacterium tuberculosis Isolates in and around Mumbai
    Joshi, Suvarna
    Dahake, Ritwik
    Chitalia, Vidushi
    Vaidya, Shashikant
    Chowdhary, Abhay
    JOURNAL OF PURE AND APPLIED MICROBIOLOGY, 2015, 9 (03): : 2263 - 2270
  • [27] Fluoroquinolone and pyrazinamide resistance in multidrug-resistant tuberculosis
    Pierre-Audigier, C.
    Surcouf, C.
    Cadet-Daniel, V.
    Namouchi, A.
    Heng, S.
    Murray, A.
    Guillard, B.
    Gicquel, B.
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2012, 16 (02) : 221 - 223
  • [28] MULTIDRUG-RESISTANT TUBERCULOSIS IN PATIENTS WITH AIDS
    DIPERRI, G
    VENTO, S
    CAZZADORI, A
    BONORA, S
    CONCIA, E
    ARCHIVES OF INTERNAL MEDICINE, 1995, 155 (13) : 1452 - 1453
  • [29] Comorbidome in multidrug-resistant tuberculosis patients
    Ivanova, Diana
    Borisov, Sergey
    Nikolenko, Nickolay
    Kosenkov, Sergey
    EUROPEAN RESPIRATORY JOURNAL, 2020, 56
  • [30] Management of patients with multidrug-resistant tuberculosis
    Lange, C.
    Aarnoutse, R. E.
    Alffenaar, J. W. C.
    Bothamley, G.
    Brinkmann, F.
    Costa, J.
    Chesov, D.
    van Crevel, R.
    Dedicoat, M.
    Dominguez, J.
    Duarte, R.
    Grobbel, H. P.
    Guenther, G.
    Guglielmetti, L.
    Heyckendorf, J.
    Kay, A. W.
    Kirakosyan, O.
    Kirk, O.
    Koczulla, R. A.
    Kudriashov, G. G.
    Kuksa, L.
    van Leth, F.
    Magis-Escurra, C.
    Mandalakas, A. M.
    Molina-Moya, B.
    Peloquin, C. A.
    Reimann, M.
    Rumetshofer, R.
    Schaaf, H. S.
    Schon, T.
    Tiberi, S.
    Valda, J.
    Yablonskii, P. K.
    Dheda, K.
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2019, 23 (06) : 645 - 662